Senate bill · S. 2121 (119th Congress)
SUPPORT for Patients and Communities Reauthorization Act of 2025
U.S. Senate
Sponsor: Bill Cassidy (U.S. Senator for Louisiana, Republican)
Following needs an Agora account. You will sign in first, then come back to this page.
From Congress.gov and official rosters. This record was last updated Aug 1, 2026. About our data
Summary
SUPPORT for Patients and Communities Reauthorization Act of 2025 This bill reauthorizes and revises Department of Health and Human Services (HHS) programs that address substance use disorders, overdoses, and mental health. For example, the bill reauthorizes for FY2026-FY2030 grant and other programs relating to • addressing substance use disorders with respect to pregnant and postpartum women, • prevention and recovery from substance use disorders for youth, • housing for individuals in recovery from substance use disorders, • community organizations facilitating recovery from substance use disorders, • loan repayment for certain health care providers treating substance use disorders, • prevention of overdoses of controlled substances, • treatment of children experiencing psychological trauma, and • mental and behavioral health education and training for medical and allied health students. Also, the bill revises several programs, including by (1) expanding a program that supports resources for first responders to include the purchase of drugs or devices to treat non-opioid overdoses, (2) expanding a program that supports employment services for individuals in recovery so as to allow for the provision of related transportation services, and (3) temporarily authorizing a regional technical assistance center to assist the National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support. Additionally, the bill establishes new requirements for HHS, including requirements relating to • protecting the National Suicide Prevention Lifeline program from cybersecurity threats, • establishing a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and • reviewing and potentially revising the scheduling of approved products containing a combination of buprenorphine and naloxone under the Controlled Substances Act.
Summary from the Congressional Research Service. How we handle summaries
Where it stands
Assigned to a committee for review.
- Introduced
- In committee
- Up for a vote
- Passed one chamber
- Passed
- Enacted
Committee
Senate Committee on Health, Education, Labor, and Pensions · U.S. Senate
Your position on this bill
Choose the position closest to yours. You'll sign in or create an account to save it.
Cosponsors
8
Showing the 7 who are on Agora, A to Z. Congress.gov listed 8 as of Jul 31, 2026.
See all cosponsors on Congress.gov (opens in a new tab)- Democratic3
- Republican3
- Other1
This bill has cosponsors from more than one party.
Party is shown for the 7 cosponsors who are on Agora.
Shown in neutral colors by design; Agora is non-partisan.
Related bills
- H.R. 9129–8–8 Lifeline Cybersecurity Responsibility ActRelated bill
- H.R. 1768Lower Costs for Everyday Americans ActRelated bill
- H.R. 2483SUPPORT for Patients and Communities Reauthorization Act of 2025Related bill, contained in public law
- H.R. 4079Safer Response Act of 2025Related bill
- S. 500CAREER Act of 2025Related bill
Show all 9 related billsShow fewer related bills
As identified by Congress.gov.
Full history
- Jun 18, 2025
Introduced
Introduced in U.S. Senate
U.S. Senate
- Jun 18, 2025
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Jun 18, 2025
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Jun 18, 2025
Referred to committee
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Read the record
- Read on Congress.gov (opens in a new tab) The official record on Congress.gov.